Population pharmacokinetic assessment of a new regimen of mefloquine used in combination treatment of uncomplicated falciparum malaria.
about
New Fixed-Dose Artesunate-Mefloquine Formulation against Multidrug-Resistant Plasmodium falciparum in Adults: a Comparative Phase IIb Safety and Pharmacokinetic Study with Standard-Dose Nonfixed Artesunate plus MefloquineNonlinear mixed-effects modelling of in vitro drug susceptibility and molecular correlates of multidrug resistant Plasmodium falciparumEfficacy and day 7 plasma piperaquine concentrations in African children treated for uncomplicated malaria with dihydroartemisinin-piperaquineTreatment of asymptomatic carriers with artemether-lumefantrine: an opportunity to reduce the burden of malaria?Compliance with a three-day course of artesunate-mefloquine combination and baseline anti-malarial treatment in an area of Thailand with highly multidrug resistant falciparum malariaPopulation pharmacokinetics of mefloquine, administered as a fixed-dose combination of artesunate-mefloquine in Indian patients for the treatment of acute uncomplicated Plasmodium falciparum malaria.Population pharmacokinetics and pharmacodynamic considerations of amodiaquine and desethylamodiaquine in Kenyan adults with uncomplicated malaria receiving artesunate-amodiaquine combination therapy.Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trial.The story of artesunate-mefloquine (ASMQ), innovative partnerships in drug development: case study.Modelling the time course of antimalarial parasite killing: a tour of animal and human models, translation and challengesOptimal designs for population pharmacokinetic studies of the partner drugs co-administered with artemisinin derivatives in patients with uncomplicated falciparum malariaTherapeutic efficacy and safety of dihydroartemisinin-piperaquine versus artesunate-mefloquine in uncomplicated Plasmodium falciparum malaria in India.Effect of artesunate-mefloquine fixed-dose combination in malaria transmission in Amazon basin communities.Assessing the utility of an anti-malarial pharmacokinetic-pharmacodynamic model for aiding drug clinical development.Population pharmacokinetics of mefloquine, piperaquine and artemether-lumefantrine in Cambodian and Tanzanian malaria patients.Towards optimal design of anti-malarial pharmacokinetic studies.Modeling within-host effects of drugs on Plasmodium falciparum transmission and prospects for malaria elimination.Effect of artesunate and mefloquine in combination on the Fridericia corrected QT intervals in Plasmodium falciparum infected adults from Thailand.Population pharmacokinetics of orally administered mefloquine in healthy volunteers and patients with uncomplicated Plasmodium falciparum malaria.Assessment of the effect of mefloquine on artesunate pharmacokinetics in healthy male volunteers.Pharmacometrics: opportunity for reducing disease burden in the developing world: the case of Africa.First assessment in humans of the safety, tolerability, pharmacokinetics, and ex vivo pharmacodynamic antimalarial activity of the new artemisinin derivative artemisonePharmacokinetic considerations for use of artemisinin-based combination therapies against falciparum malaria in different ethnic populations.Pharmacokinetics of mefloquine administered with artesunate in patients with uncomplicated falciparum malaria from the Brazilian Amazon basinPopulation pharmacokinetics of mefloquine given as a 3-day artesunate-mefloquine in patients with acute uncomplicated Plasmodium falciparum malaria in a multidrug-resistant area along the Thai-Myanmar border
P2860
Q22061804-56DC80B3-A68F-4A86-8BEA-598FA7237F31Q28534820-199A69AF-B263-40D4-B8B6-A44463CB11BEQ28542034-9FFB5A87-24ED-4620-B09D-F8A6505F7E13Q33670134-5741DB8D-DD7C-40EB-8D35-5BFBAF837014Q33692416-E25F3A3C-3A0B-40AB-8B76-5A6536018D52Q33713272-A540F04E-6572-494A-9178-E6B72B415977Q33876535-75BC8659-71FA-4FDD-A0F0-9DE1BBC96CD5Q34164652-486AE54A-5970-483D-B91F-76731224F0BEQ34329292-2A465803-CA49-4CFB-87F1-A8671EA48D82Q34953705-B80F1F36-414D-4937-9AD8-D52896E1E119Q36088256-78A6C679-DB80-4BB3-A337-7F9D808E127EQ36179156-C637FF83-1EC2-470B-A918-F0BE4EA769D7Q36320208-27F4CF65-A74D-4B01-A888-92AEAC28ACAAQ36539049-DBDBCC9D-C298-46BE-BAD7-105E71968D89Q37038270-04CC0FDE-1F08-4F2F-817D-12B1F05D98F7Q37320525-621ECAA8-FE72-4CA8-B665-27313E33CD51Q37509562-37D0921B-8E6A-4312-A56D-51240F2335FCQ39149101-CE61A070-6D6C-4637-8986-4867B47F9362Q39394101-DB546F25-D1B0-434F-BD2B-F72513F90B2DQ42137131-85659FCC-EF81-49F5-9479-339736021A98Q42249532-2E7B8CA0-CF04-4A38-AA35-E70387F7DDE2Q42445249-EAE7AE09-27ED-465E-8EA8-2C1E16630007Q46405195-992023F8-0169-4A21-8CAD-CE99D4A1B334Q56363318-3F6C3071-F54E-4298-A90D-7282C1CB6DE2Q58768200-20A68F5F-AF57-4961-AD56-35B183AA23FA
P2860
Population pharmacokinetic assessment of a new regimen of mefloquine used in combination treatment of uncomplicated falciparum malaria.
description
2006 nî lūn-bûn
@nan
2006 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Population pharmacokinetic ass ...... omplicated falciparum malaria.
@ast
Population pharmacokinetic ass ...... omplicated falciparum malaria.
@en
Population pharmacokinetic ass ...... omplicated falciparum malaria.
@nl
type
label
Population pharmacokinetic ass ...... omplicated falciparum malaria.
@ast
Population pharmacokinetic ass ...... omplicated falciparum malaria.
@en
Population pharmacokinetic ass ...... omplicated falciparum malaria.
@nl
prefLabel
Population pharmacokinetic ass ...... omplicated falciparum malaria.
@ast
Population pharmacokinetic ass ...... omplicated falciparum malaria.
@en
Population pharmacokinetic ass ...... omplicated falciparum malaria.
@nl
P2093
P2860
P50
P356
P1476
Population pharmacokinetic ass ...... omplicated falciparum malaria.
@en
P2093
Elizabeth A Ashley
Niklas Lindegårdh
Robert Hutagalung
P2860
P304
P356
10.1128/AAC.00040-06
P407
P577
2006-07-01T00:00:00Z